GlobeNewswire by notified

Taconic Biosciences Announces the Formation of Scientific Advisory Board

Share

RENSSELAER, N.Y., Feb. 21, 2018 (GLOBE NEWSWIRE) -- Taconic Biosciences, a global leader in genetically engineered mouse models and associated services, announced the formation of its Scientific Advisory Board (SAB) with the initial appointments of J. Victor Garcia, PhD, Andrew Goodman, PhD, and David Hill, PhD.

The SAB will collaborate with Taconic's management in providing scientific insight and guidance on the evolution of the company's product and service portfolios. Capitalizing on Taconic's existing leadership in both the microbiome and immuno-oncology spaces, the SAB members bring complementary expertise to continue to drive innovation in these and other research areas.

"Discovery and pre-clinical animal models continue to move toward highly-complex and high-value translational models. To continue to provide the best solutions for our customers, it is essential for Taconic to have guidance from prominent scientific experts as we develop and validate new models and services," shared Bob Rosenthal, CEO of Taconic Biosciences. 

Dr. J. Victor Garcia is a Professor of Medicine in the Center for AIDS Research (CFAR), the Institute for Global Health & Infectious Diseases (IGHID), and the Division of Infectious Diseases in the Department of Medicine, all at the University of North Carolina at Chapel Hill. He is an Oliver Smithies Investigator and a Fellow of the American Academy of Microbiology. Throughout his career, Dr. Garcia has established himself as an expert in the development, implementation, and use of humanized mice for biomedical research, particularly in the area of infectious disease. Dr. Garcia received a Bachelor of Science in chemistry from the Instituto Tecnológico y de Estudios Superiores de Monterrey and a PhD in chemistry from Georgetown University.

Dr. Andrew Goodman is an Associate Professor of Microbial Pathogenesis and a member of the Microbial Sciences Institute at Yale University School of Medicine. For this work, Dr. Goodman has been recognized with the NIH Director's New Innovator Award, the Pew Scholars Fellowship, DuPont Young Professor Award, Burroughs Wellcome Fund Investigator Award, Howard Hughes Medical Institute Faculty Scholar Award, and the Presidential Early Career Award in Science and Engineering. Dr. Goodman's research is focused on understanding the mechanisms of interaction between members of the human gut microbiome and with the host. The Goodman Lab combines microbial genetics, gnotobiotic animal models, and computational approaches to develop new technologies for studying the microbiome and to apply these approaches to uncover the causes and consequences of interpersonal microbiome variation. Dr. Goodman was trained in ecology and evolutionary biology at Princeton University and completed his PhD in microbiology at Harvard Medical School.

Dr. David Hill has established a successful and extensive career leading the pharmacology departments of many major pharmaceutical companies, including a combined twenty years at Organon and Merck.  Dr. Hill's therapeutic expertise includes neuroscience, pain, anesthesia, cardiometabolic disease, and oncology. During his career, Dr. Hill played a pivotal role in directing preclinical animal model programs of various sizes that resulted in many new approved therapeutics. Beyond his scientific expertise, Dr. Hill also brings a keen knowledge of harmonizing internal and outsourced resources to produce both sound scientific and business results. Dr. Hill earned a Bachelor of Science in applied biology from Hatfield Polytechnic and a PhD in pharmacology from St. Thomas Hospital Medical School.

To learn more about Taconic's products and services, please call 1-888-TACONIC  (888-822-6642 ) in the US, +45 70 23 04 05  in Europe, or email  info@taconic.com .

About Taconic Biosciences, Inc.
Taconic Biosciences is a fully-licensed, global leader in genetically engineered rodent models and services. Founded in 1952, Taconic provides the best animal solutions so that customers can acquire, custom generate, breed, precondition, test, and distribute valuable research models worldwide. Specialists in genetically engineered mouse and rat models, precision research mouse models, and integrated model design and breeding services, Taconic operates three service laboratories and six breeding facilities in the U.S. and Europe, maintains distributor relationships in Asia and has global shipping capabilities to provide animal models almost anywhere in the world.

Media Contact:
Kelly Owen Grover
Director of Marketing Communications
(518) 697-3824
kelly.grover@taconic.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Taconic Biosciences via Globenewswire

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Decisions of Sampo plc’s Annual General Meeting25.4.2024 15:35:00 CEST | Press release

SAMPO PLC DECISIONS OF GENERAL MEETING 25 April 2024 at 4:35 pm Decisions of Sampo plc’s Annual General Meeting The Annual General Meeting of Sampo plc, held today on 25 April 2024, approved all the proposals made to the AGM by the Board of Directors and its Committees, including distribution of dividend of EUR 1.80 per share for 2023. The AGM adopted the financial accounts for 2023 and discharged the members of the Board of Directors and CEO from liability for the financial year ending 31 December 2023. The AGM authorised the Board of Directors to decide on share repurchases and a share issue without payment. Including proxy representatives, there were altogether 320,218,518 shares (63.8 per cent of shares) and 321,018,518 votes (63.9 per cent of all votes) in the company represented at the Annual General Meeting. Dividend payment The AGM decided to distribute a dividend of EUR 1.80 per share for 2023. The dividend will be paid to the shareholders registered in the Company’s sharehold

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)25.4.2024 15:30:00 CEST | Press release

ORION CORPORATION STOCK EXCHANGE RELEASE – MAJOR SHAREHOLDER ANNOUNCEMENTS 25 APRIL 2024 at 16.30 EEST Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.) Orion Corporation has received a disclosure under Chapter 9, Section 5 of the Securities Market Act, according to which the total number of Orion shares owned directly, indirectly and through financial instruments by BlackRock, Inc. and its funds increased on 24 April 2024 above five (5) per cent of Orion Corporation’s total shares. Total positions of BlackRock, Inc. and its funds subject to notification: % of shares and voting rights (total of point A)% of shares and voting rights through financial instruments (total of point B)Total of both in % (points A + B)Total number of shares and voting rights of issuerResulting situation on the date on which threshold was crossed or reached4.99% shares Below 5% voting rights0.02% shares Below 5% voting rights5.01% shares Below 5% voting rig

Årsstämma PolyPlank AB (publ)25.4.2024 15:29:47 CEST | Pressemelding

PolyPlank AB (publ) har hållit årsstämma på Bolagets kontor, Färjestaden, Öland. Samtliga beslut fattades enligt styrelsens förslag fram till punkt 8c samt punkt 13 som flyttades fram före punkt 9. Punkt 9-12 ajournerades till fortsatt stämma att hållas den 13 juni 2024. Ny kallelse publiceras senast fyra veckor före den fortsatta stämman. Stämman beslutade att fastställa de i årsredovisningen intagna resultat- och balansräkningarna samt koncernresultaträkning och koncernbalansräkning.Stämman beslutade att behandla det uppkomna resultatet i enlighet med styrelsens förslag i årsredovisningen.Stämman beviljade styrelsens ledamöter och verkställande direktören ansvarsfrihet för förvaltningen under det gångna året.Stämman beslutade att enligt styrelsens förslag minska det registrerade aktiekapitalet för att ge större utrymme för att täcka förluster som inte täcks av fritt eget kapital. Minskning ska ske utan indragning av aktier. För ytterligare information, vänligen kontakta: Vd Marina Ab

Proceedings at the extraordinary general meeting on April 25, 202425.4.2024 15:27:01 CEST | Press release

Company announcement no 6-2024 Søborg, April 15, 2024 Proceedings at the extraordinary general meeting on April 25, 2024 An extraordinary general meeting of Konsolidator A/S took place on April 25, 2024 at Konsolidator A/S, Vandtårnsvej 83A, 2., DK-2860 Søborg, in accordance with the agenda. The board of directors elected Jakob Vig Schnack, attorney-at-law, as chairman of the meeting. The general meeting approved the only item on the agenda, which was the proposal by the board of directors to include a new authorization in the articles of association for the board of directors to increase the share capital with a nominal value of up to DKK 240,000 without pre-emption rights for the existing shareholders. The minutes of the extraordinary general meeting and the updated articles of association are available at www.konsolidator.com/investors/ and attached to this announcement. Contacts CEO: Claus Finderup Grove, mobile +45 2095 2988, cfg@konsolidator.comCFO: Jack Skov, mobile, +45 2282 88

A larger Hispack seeks to accelerate responsible packaging solutions25.4.2024 15:19:14 CEST | Press release

BARCELONA, Spain, April 25, 2024 (GLOBE NEWSWIRE) -- Hispack 2024 will focus on sustainable packaging to contribute to a better future. From May 7 to 10, Spain's largest packaging tradeshow will gather 780 exhibitors from 28 countries and 1,250 brands at Fira de Barcelona's Gran Via venue to showcase the latest innovations in materials, packaging, containers, labels, wrapping, processing, and logistics technology and machinery. Over 27,000 attendees are expected at the 2024 edition. Organized by Fira de Barcelona in collaboration with Graphispack Association, Hispack 2024 will grow by 18% in number of companies and 12% in exhibition space and will spread over 36,000 m2 in halls 2 and 3 featuring leading manufacturers and distributors with the latest technology, materials and packaging solutions focusing on sustainability. This event has also registered an increase in the number of international exhibitors, with almost a third of the total coming from outside Spain. Turkey will lead the

HiddenA line styled icon from Orion Icon Library.Eye